How cannabis extractors can ensure their organic products stay clean

Organic marijuana and hemp products can fetch two and three times more than conventional cannabis, but the path to market is trickier than simply growing the plant without common pesticides.

Aurora Cannabis CEO discusses greenhouse ‘arms race’ and firm’s future

CEO Miguel Martin discusses lessons learned from Aurora Cannabis’ past and how the firm’s transformation plan will impact the future.

No hallucination: Psychedelics could be next cannabis-like boom

Investors as well as cannabis companies and executives are rushing into psychedelics, a multibillion-dollar opportunity that reminds some of the early days of marijuana – although this infant industry could play out much differently.

Aphria and Tilray to merge, creating CA$5 billion global cannabis giant

Canadian cannabis companies Aphria and Tilray on Wednesday announced plans to merge, a transaction that would create a giant international marijuana firm with combined equity value of approximately 5 billion Canadian dollars ($3.9 billion).

United Nations approves WHO recommendation to reschedule cannabis in historic vote

The United Nations Commission on Narcotic Drugs (CND) on Wednesday accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.

Appellation program, cooperatives might give small California cannabis farmers a boost

Small marijuana farmers in California who’ve struggled in recent years – either to launch their own brands, expand their businesses or survive the transition to the new legal market – might have a brighter future, thanks in part to various programs and ventures now in the works.

CBD not a narcotic, EU court says, potentially opening new market

The European Union’s top court ruled that CBD derived from the entire industrial hemp plant is not a narcotic, paving the way for new business opportunities for low-THC marijuana producers to sell outside the highly regulated pharmaceutical channels in Europe.

Epidiolex maker GW Pharma reports record quarterly revenue of $137 million

United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales of its cannabidiol medicine Epidiolex.